GSK: applies to EMA for expanded indication for Jemperli

(CercleFinance.com) - GSK has announced that the European Medicines Agency (EMA) has agreed to consider its request to extend the use of Jemperli (dostarlimab) in combination with standard chemotherapy to all adult patients with advanced or recurrent endometrial cancer.


If approved, dostarlimab could be used for all biomarker types, including MMRp/MSS, where there is as yet no first-line immunotherapy treatment.

This application is based on results from a phase III trial which showed a significant benefit in terms of progression-free survival and overall survival with dostarlimab plus chemotherapy compared with chemotherapy alone.

EMA approval is expected in H1 2025.


Copyright (c) 2024 CercleFinance.com. All rights reserved.